Literature DB >> 8063866

An old enzyme with a new function: purification and characterization of a distinct matrix-degrading metalloproteinase in rat kidney cortex and its identification as meprin.

G P Kaushal1, P D Walker, S V Shah.   

Abstract

We have purified to homogeneity the enzyme in the kidney cortex which accounts for the vast majority of matrix-degrading activity at neutral pH. The purified enzyme has an apparent molecular mass of 350 kD by gel filtration and of 85 kD on SDS-PAGE under reducing conditions; and it degrades laminin, type IV collagen and fibronectin. The enzyme was inhibited by EDTA and 1,10-phenanthroline, but not by other proteinase inhibitors. The enzyme was not activated by organomercurials or by trypsin and was not inhibited by tissue inhibitors of metalloproteinases indicating that it is distinct from the other matrix-degrading metalloproteinases. Unexpectedly, the amino acid sequence of the NH2-terminal and two internal peptides of the enzyme showed complete homology to those alpha subunits of rat meprin, an enzyme previously shown to degrade azocasein and insulin B chain but not known to degrade extracellular matrix components. Immunoprecipitation studies, Western blot analyses and other biochemical properties of the purified enzyme confirm that the distinct matrix-degrading enzyme is indeed meprin. Our data also demonstrate that meprin is the major enzyme in the renal cortex capable of degrading components of the extracellular matrix. The demonstration of this hitherto unknown function of meprin suggests its potential role in renal pathophysiology.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8063866      PMCID: PMC2120165          DOI: 10.1083/jcb.126.5.1319

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  24 in total

Review 1.  Development of kidney tubular basement membranes.

Authors:  D R Abrahamson; V Leardkamolkarn
Journal:  Kidney Int       Date:  1991-03       Impact factor: 10.612

Review 2.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

Review 3.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

Authors:  J F Woessner
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

4.  A novel metalloproteinase present in freshly isolated rat glomeruli.

Authors:  Q Le; S Shah; H Nguyen; S Cortez; W Baricos
Journal:  Am J Physiol       Date:  1991-04

Review 5.  Meprin: a membrane-bound metallo-endopeptidase.

Authors:  J S Bond; R J Beynon
Journal:  Curr Top Cell Regul       Date:  1986

6.  Distribution of meprin in kidneys from mice with high- and low-meprin activity.

Authors:  S S Craig; J F Reckelhoff; J S Bond
Journal:  Am J Physiol       Date:  1987-10

7.  The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family.

Authors:  H E Van Wart; H Birkedal-Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

8.  Homo- and heterotetrameric forms of the membrane-bound metalloendopeptidases meprin A and B.

Authors:  C M Gorbea; A V Flannery; J S Bond
Journal:  Arch Biochem Biophys       Date:  1991-11-01       Impact factor: 4.013

9.  Cloning a rat meprin cDNA reveals the enzyme is a heterodimer.

Authors:  G D Johnson; L B Hersh
Journal:  J Biol Chem       Date:  1992-07-05       Impact factor: 5.157

10.  Meprin-A and -B. Cell surface endopeptidases of the mouse kidney.

Authors:  M Z Kounnas; R L Wolz; C M Gorbea; J S Bond
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.157

View more
  31 in total

Review 1.  The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family.

Authors:  G P Kaushal; S V Shah
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

2.  Human N-benzoyl-L-tyrosyl-p-aminobenzoic acid hydrolase (human meprin): genomic structure of the alpha and beta subunits.

Authors:  D Hahn; R Illisson; A Metspalu; E E Sterchi
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

Review 3.  Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury.

Authors:  Philip R Mayeux; Lee Ann MacMillan-Crow
Journal:  Pharmacol Ther       Date:  2012-01-16       Impact factor: 12.310

Review 4.  The astacin family of metalloendopeptidases.

Authors:  J S Bond; R J Beynon
Journal:  Protein Sci       Date:  1995-07       Impact factor: 6.725

Review 5.  Extracellular matrix and the kidney.

Authors:  P N Furness
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

6.  Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis.

Authors:  R Kalluri; C F Shield; P Todd; B G Hudson; E G Neilson
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

Review 7.  Meprin A metalloproteinase and its role in acute kidney injury.

Authors:  Gur P Kaushal; Randy S Haun; Christian Herzog; Sudhir V Shah
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-20

Review 8.  Role of meprin metalloproteinases in cytokine processing and inflammation.

Authors:  Christian Herzog; Randy S Haun; Gur P Kaushal
Journal:  Cytokine       Date:  2018-12-20       Impact factor: 3.861

9.  Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors.

Authors:  Markus-N Kruse; Christoph Becker; Daniel Lottaz; Danny Köhler; Irene Yiallouros; Hans-Willi Krell; Erwin E Sterchi; Walter Stöcker
Journal:  Biochem J       Date:  2004-03-01       Impact factor: 3.857

Review 10.  Meprins, membrane-bound and secreted astacin metalloproteinases.

Authors:  Erwin E Sterchi; Walter Stöcker; Judith S Bond
Journal:  Mol Aspects Med       Date:  2008-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.